Pramipexole and levodopa in early Parkinson's disease: Dynamic changes in cost effectiveness

PharmacoEconomics

Volumn 23, Issue 12, 2005, Pages 1257-1270

  Noyes, Katia ^a   Dick, Andrew W ^a,b   Holloway, Robert G ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b RAND CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; PRAMIPEXOLE;

ADULT; AGED; ANALYTICAL ERROR; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DYSKINESIA; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SAMPLE SIZE; SENSITIVITY ANALYSIS; STATISTICAL MODEL; TIME SERIES ANALYSIS; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; HEALTH EXPENDITURES; HUMANS; LEVODOPA; MALE; PARKINSON DISEASE; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SEX FACTORS; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 29144516348     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200523120-00009     Document Type: Article

References (54)

1. Marras C, Lang A, Krahn M, et al. Quality of life in early Parkinson's disease: the impact of dyskinesias and motor fluctuations. Mov Disord 2004; 19 (1): 22-8
2. Hoerger TJ, Bala MV, Rowland C, et al. Cost effectiveness of pramipexole in Parkinson's disease in the US. Pharmacoeconomics 1998; 15 (5): 541-67
3. LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999; 16 (1): 59-69
4. Rubenstein LM, DeLeo A, Chrischilles EA. Economic and health-related quality of life considerations of new therapies in Parkinson's disease. Pharmacoeconomics 2001; 19 (7): 729-52
5. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilization in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001; 19 (10): 1013-38
6. US Food and Drug Administration, Department of Health and Human Services. Approvals of FDA-regulated products [on-line]. Available from URL: http://www.fda.gov/opacom/7approvl.html [Accessed 2005 Sep 22]
7. Zielinski SL. FDA attempting to overcome major roadblocks in monitoring drug safety. J Natl Cancer Inst 2005 Jun 15; 97 (12): 872-3
8. Noyes K, Dick AW, Holloway RG, et al. Pramipexole vs levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial. The Parkinson Study Group. Med Decis Making 2004; 24: 472-85
9. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000; 284: 1931-8
10. Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-53
11. Noyes K, Dick AW, Holloway RG, et al. Quality of life assessment of early Parkinson. Med Decis Making 2003; 23 (6): 248
12. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD study. Clin Neuropharmacol 2000; 23 (1): 34-44
13. Ramsey SD, McIntosh M, Sullivan SD. Design issues for conducting cost-effectiveness analyses alongside clinical trials. Annu Rev Public Health 2001; 22: 129-41
14. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, et al., editors. Recent developments in Parkinson's disease. Vol 2. Macmillian Health Care Information; Florman Park (NJ), 1987: 153-64
15. Dolan P. Modelling valuations for EuroQol health states. Med Care 1997; 11: 1095-108
16. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005; 43: 203-20
17. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for economic evaluation of health care programmes. 2nd ed. Oxford, UK: Oxford University Press, 1997
18. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
19. Siderowf A, Ravina B, Glick HA. Preference-based quality-of-life in patients with Parkinson's disease. Neurology 2002; 59 (1): 103-8
20. Brazier JE, Walters SJ, Nicholl JP, et al. Using the SF-36 and EuroQoL on an elderly population. Qual Life Res 1996; 5 (2): 195-204
21. Federal Register (1994) Part II: 42 CFR Parts 410 and $14 Medicare program. Physician Fee Schedule for Calendar Year 1995; Payment Policies and Relative Value Unit Adjustments. Vol. 59, No. 235. Washington, DC: US Government Printing Office, 1994
22. Center for Medicare and Medicaid Services. DRG definitions manual version 18, effective 1-1-2001. St. Paul (MN): 3M Health Information Systems, 2000
23. US Census Bureau. Statistical abstract of the United States: 2000. Table no. 750: money income of persons. Washington, DC: Government Printing Office, 2000
24. Gabrel CS. An overview of nursing home facilities: data from the 1997 National Nursing Home Survey. Hyattsville (MD): National Center for Health Statistics, 2000
25. The Red Book Drug Topics. Montvale (NJ): Medical Economics Company Inc, 2001
26. Williams RM. The costs of visits to emergency departments. N Engl J Med 1996; 334: 642-6
27. Torrance GW, Siegel J, Luce BR. Framing and designing the cost-effectiveness analysis. In: Gold MR, Russell LB, Siegel JE, et al., editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996: 54-81
28. Meltzer D, Johannesson M. Inconsistencies in the 'societal perspective' on costs of the panel on cost-effectiveness in heath and medicine. Med Decis Making 1999; 19: 371-7
29. Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol 2003; 56: 968-76
30. Duan N, Manning WG, Morris CN, et al. Choosing between the sample selection model and multi-part model. J Bus Econ Stat 1984; 2: 283-9
31. Torrance GW, Tugwell P, Amorosi S, et al. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. Rheumatology 2004; 43: 712-8
32. Consumer price index. Washington, DC: US Department of Labor, Bureau of Labor Statistics [online]. Available from URL: http://www.bl s.gov/cpi [Accessed 2005 Nov 4]
33. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002; 11 (5): 415-30
34. Stinnett AA, Mullahy J. Net health benefit: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18 (2 Suppl.): S68-80
35. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions. Health Econ 2004; 13 (5): 405-15
36. Van Hout BA, Alm J, Gordon GS, et al. Cost, effects and C/E ratios alongside a clinical trial. Health Econ 1994; 3: 309-19
37. Hariz GM, Lindberg M, Hariz MI, et al. Gender differences in disability and health-related quality of life in patients with Parkinson's disease treated with stereotactic surgery. Acta Neurol Scand 2003; 108 (1): 28-37
38. Karlsen KH, Larsen JP, Tandberg E, et al. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 66 (4): 431-5
39. Karlsen KH, Tandberg E, Arsland D, et al. Health-related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 2000; 69 (5): 584-9
40. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977; 296 (13): 732-9
41. Sanders GD, Hlatky MA, Every NR, et al. Potential cost-effectiveness of prophylactic use of the implantable cardiac defibrillators and amiodarone after myocardial infarction. Ann Intern Med 2001; 135: 870-83
42. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass graft surgery. Circulation 1982; 66 (5 pt 2): III56-66
43. Williams A. Economics of coronary bypass grafting. BMJ 1985; 291 (6491): 326-9
44. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163 (14): 1637-41
45. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Eng J Med 2000; 342: 1484-91
46. Baker CB, Johnsrud MT, Crismon ML, et al. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 2003 Dec; 183: 498-506
47. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis: an illustration and application to blood pressure control in type 2 diabetes. Int J Technol Assess Health Care 2001; 17 (1): 69-82
48. Angell M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House, 2004
49. Greider K. The big fix: how the pharmaceutical industry rips off American consumers. Cambridge (MA): Public Affairs, 2003
50. Salomon JA, Weinstein MC, Goldie SJ, et al. Taking account of future technology in cost-effectiveness analysis. BMJ 2004; 329: 733-6
51. Coyle D, Barbeau M, Guttman M, et al. The economic evaluation of pharmacotherapies for Parkinson's disease. Parkinsonism Relat Disord 2003; 9 (5): 301-7
52. Gold MR, Stevenson D, Fryback DG. HALYs and QALYs and DALYs, oh my: similarities and differences in summary measures of population health. Annu Rev Public Health 2002; 23: 115-34
53. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression [letter]. Am J Psychiatry 1999; 156 (5): 798
54. Maggio R, Scarselli M, Novi F, et al. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem 2003; 87 (3): 631-41